An investigational trial comparing the efficacy and safety of once weekly NNC0148-0287 C (insulin 287) versus once daily insulin glargine, both in combination with metformin, with or without DPP-4 inhibitors, in insulin naïve subjects with type 2 diabetes mellitus
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Insulin 287 (Primary) ; Insulin glargine; Metformin
- Indications Diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 29 Oct 2019 Planned primary completion date changed from 3 Oct 2019 to 16 Dec 2019.
- 25 Jun 2019 Planned End Date changed from 3 Jan 2020 to 20 Jan 2020.
- 25 Jun 2019 Status changed from recruiting to active, no longer recruiting.